EDG-5506 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
113	筋ジストロフィー	3

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05540860 (ClinicalTrials.gov)	October 24, 2022	6/9/2022	A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy	A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B	Duchenne Muscular Dystrophy	Drug: EDG-5506 Dose 1;Drug: EDG-5506 Dose 2;Drug: EDG-5506 Dose 3;Drug: Placebo	Edgewise Therapeutics, Inc.	NULL	Recruiting	4 Years	9 Years	Male	27	Phase 2	United States
2	NCT05291091 (ClinicalTrials.gov)	July 6, 2022	14/3/2022	Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (CANYON)	A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy	Becker Muscular Dystrophy	Drug: EDG-5506 Dose 1;Drug: EDG-5506 Dose 2;Drug: EDG-5506 Dose 3;Drug: EDG-5506 Dose 4;Drug: EDG-5506 Dose 5;Drug: Placebo	Edgewise Therapeutics, Inc.	Medpace, Inc.	Recruiting	12 Years	50 Years	Male	66	Phase 2	United States;Netherlands;United Kingdom
3	NCT05160415 (ClinicalTrials.gov)	December 28, 2021	2/12/2021	A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy	A Phase 1b, Open-label Study of the Safety and Pharmacokinetics of EDG-5506 in Adults With Becker Muscular Dystrophy	Becker Muscular Dystrophy	Drug: EDG-5506	Edgewise Therapeutics, Inc.	Medpace, Inc.	Active, not recruiting	18 Years	55 Years	Male	12	Phase 1	United States